van der Aart‐van der Beek AB, van Raalte DH, Guja C, et al. - In patients with type 2 diabetes (T2D) and increased urine albumin‐to‐creatinine ratio (uACR), researchers investigated the albuminuria‐lowering impact of exenatide once weekly (EQW) compared with active glucose‐lowering comparators. Six randomized double‐blind and open‐label phase III studies were pooled in a post‐hoc, exploratory analysis to determine the safety and effectiveness of EQW vs non‐GLP1 comparators in T2D patients and baseline uACR ≥ 30 mg/g. In patients with T2D and elevated albuminuria, EQW lowered uACR compared with widely used glucose-lowering medications.